中国组织工程研究 ›› 2023, Vol. 27 ›› Issue (26): 4214-4222.doi: 10.12307/2023.530
• 组织构建综述 tissue construction review • 上一篇 下一篇
赵 圆,翟浩嫣,刘春艳
收稿日期:
2022-08-05
接受日期:
2022-09-21
出版日期:
2023-09-18
发布日期:
2023-01-28
通讯作者:
刘春艳,女,博士,副主任医师,副教授,河北医科大学口腔医(学)院正畸科,河北省口腔医学重点实验室,河北省口腔疾病临床医学研究中心,河北省石家庄市 050017
作者简介:
赵圆,女,1998年生,河北医科大学口腔医院硕士研究生在读。
基金资助:
Zhao Yuan, Zhai Haoyan, Liu Chunyan
Received:
2022-08-05
Accepted:
2022-09-21
Online:
2023-09-18
Published:
2023-01-28
Contact:
Liu Chunyan, MD, Associate chief physician, Associate professor, Department of Orthodontics, School and Hospital of Stomatology, Hebei Medical University, Hebei Key Laboratory of Stomatology, Hebei Clinical Research Center for Oral Diseases, Shijiazhuang 050017, Hebei Province, China
About author:
Zhao Yuan, Master candidate, Department of Orthodontics, School and Hospital of Stomatology, Hebei Medical University, Hebei Key Laboratory of Stomatology, Hebei Clinical Research Center for Oral Diseases, Shijiazhuang 050017, Hebei Province, China
Supported by:
摘要:
文题释义:
大麻素受体(Cannabinoid receptors,CBRs):是A类GPCRs家族的成员,其中最具有代表性的为大麻素Ⅰ型(CB1)受体、大麻素Ⅱ型(CB2)受体,为内源性大麻素系统的两种典型受体。CBRs在成骨细胞、破骨细胞等细胞表面表达,可作为靶点与大麻素配体结合,参与调节成骨细胞、破骨细胞活性,对局部炎症和免疫功能也有一定的调控作用。结果与结论:①内源性大麻素系统包含多种受体,其中最具有代表性的为CB1和CB2受体,均属于G蛋白偶联超家族成员;二者在牙周组织中均存在表达;②在天然配体或人工合成激动剂的作用下,大麻素受体可通过不同的代谢通路在体内外产生特定的生理效应,从而调控牙周炎局部的炎症和骨细胞的生成和分化,最终影响炎症和骨量;③进一步研究大麻素受体与牙周炎炎症和牙槽骨骨形成、骨吸收的关系,以及涉及到的常见信号通路——丝裂原活化蛋白激酶(MAPK)信号通路、NF-κB信号通路,为临床上牙周炎的预防和治疗提供新的思路成为目前研究的重点。
https://orcid.org/0000-0002-2222-2590(赵圆)
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程
中图分类号:
赵 圆, 翟浩嫣, 刘春艳. 大麻素受体激活调控牙周炎症和骨改建促进牙周组织愈合[J]. 中国组织工程研究, 2023, 27(26): 4214-4222.
Zhao Yuan, Zhai Haoyan, Liu Chunyan. Activation of cannabinoid receptors promotes periodontal healing by regulating periodontal inflammation and bone remodeling[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(26): 4214-4222.
[1] MECHOULAM R. The Pharmacohistory of Cannabis sativa, in Cannabis as Therapeutic Agent. CRC Press; Boca Raton, FL, USA:1986. [2] JONES É, VLACHOU S. A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020; 25(21):4930. [3] PERTWEE RG, HOWLETT AC, ABOOD ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1and CB2. Pharmacol Rev. 2010;62:588-631. [4] ZOU S, KUMAR U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. [5] LIU C, QI X, ALHABEIL J, et al. Activation of cannabinoid receptors promote periodontal cell adhesion and migration. J Clin Periodontol. 2019;46(12):1264-1272. [6] LU HC, MACKIE K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. [7] JOSEF S, ZDENĚK L, SIMONA M, et al. Endocannabinoids. Ceska Gynekol. 2021;86(6):414-420. [8] AIZPURUA-OLAIZOLA O, ELEZGARAI I, RICO-BARRIO I, et al. Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today. 2017;22(1):105-110. [9] PROSPÉRO-GARCÍA O, RUIZ CONTRERAS AE, ORTEGA GÓMEZ A, et al. Grupo de Neurociencias de la Universidad Nacional Autónoma de México. Endocannabinoids as Therapeutic Targets. Arch Med Res. 2019;50(8): 518-526. [10] IANNOTTI FA, DI MARZO V. The gut microbiome, endocannabinoids and metabolic disorders. J Endocrinol. 2021;248(2):R83-R97. [11] DIPATRIZIO NV. Endocannabinoids and the Gut-Brain Control of Food Intake and Obesity. Nutrients. 2021;13(4):1214. [12] PACHER P, KOGAN NM, MECHOULAM R. Beyond THC and Endocannabinoids. Annu Rev Pharmacol Toxicol. 2020;60:637-659. [13] ATAEI A, RAHIM REZAEE SA, MOEINTAGHAVI A, et al. Evaluation of cannabinoid receptors type 1-2 in periodontitis patients. Clin Exp Dent Res. 2022 Jun 19. doi: 10.1002/cre2.608. [14] YE L, CAO Z, WANG W, et al. New Insights in Cannabinoid Receptor Structure and Signaling. Curr Mol Pharmacol. 2019;12(3):239-248. [15] MUNRO S, THOMAS KL, ABU-SHAAR M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65 . [16] MACCARRONE M, BAB R, BIRO T, et al. Endocannabinoid signaling at the periphery: 50 years after thc. Trends Pharmacol Sci. 2015;36:277-296. [17] IZZO AA, SHARKEY KA. Cannabinoids and the gut: New developments and emerging concepts. Pharmacol. Ther. 2010;126:21-38. [18] MONTECUCCO F, DI MARZO V. At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol. Sci. 2012;33:331-340. [19] LAPRAIRIE RB, BAGHER AM, DENOVAN-WRIGHT EM. Cannabinoid receptor ligand bias: implications in the central nervous system. Curr Opin Pharmacol. 2017;32:32-43. [20] LI X, SHEN L, HUA T, et al. Structural and Functional Insights into Cannabinoid Receptors. Trends Pharmacol Sci. 2020;41(9):665-677. [21] ALVES LCV, LISBOA MRP, DA SILVEIRA HF, et al. Electroacupuncture increases immunoexpression of CB1 and CB2 receptors in experimental model of inflammatory bone loss. Bone. 2019;127:59-66. [22] LISBOA SF, GOMES FV, GUIMARAES FS, et al. Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders. Front Neurol. 2016;7:5. [23] STEMPEL AV, STUMPF A, ZHANG HY, et al.Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. Neuron. 2016; 90(4):795-809. [24] APOSTU D, LUCACIU O, MESTER A, et al.Cannabinoids and bone regeneration. Drug Metab Rev. 2019;51(1):65-75. [25] NAGOOR MEERAN MF, SHARMA C, GOYAL SN, et al. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. Drug Dev Res. 2021;82(1):7-11. [26] KOMOROWSKA-MÜLLER JA, SCHMÖLE AC. CB2 Receptor in Microglia: The Guardian of Self-Control. Int J Mol Sci. 2020;22(1):19. [27] CABAÑERO D, MARTÍN-GARCÍA E, MALDONADO R. The CB2 cannabinoid receptor as a therapeutic target in the central nervous system. Expert Opin Ther Targets. 2021;25(8):659-676. [28] KILARU A, CHAPMAN KD. The endocannabinoid system. Essays Biochem. 2020;64(3):485-499. [29] ABIDI AH, PRESLEY CS, DABBOUS M, et al. Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts. Arch Oral Biol. 2018;87:79-85. [30] SAWZDARGO M, NGUYEN T, LEE DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999;64(2):193-198. [31] MOSCA MG, MANGINI M, CIOFFI S, et al. Peptide targeting of lysophosphatidylinositol-sensing GPR55 for osteoclastogenesis tuning. Cell Commun Signal. 2021;19(1):48. [32] NISHIMURA H, KAWASAKI M, TSUKAMOTO M, et ,al .Transient receptor potential vanilloid 1 and 4 double knockout leads to increased bone mass in mice. Bone Rep. 2020;12:100268. [33] SANTAMARIA-JR M, BAGNE L, ZANIBONI E, et al. Diabetes mellitus and periodontitis: Inflammatory response in orthodontic tooth movement. Orthod Craniofac Res. 2020;23(1):27-34. [34] SUN X, GAO J, MENG X, et al. Polarized Macrophages in Periodontitis: Characteristics, Function, and Molecular Signaling. Front Immunol. 2021; 12:763334. [35] PAN W, WANG Q, CHEN Q. The cytokine network involved in the host immune response to periodontitis. Int J Oral Sci. 2019;11(3):30. [36] JEAN-GILLES L, BRAITCH M, LATIF ML, et al. Effects of pro-inflammatory cytokines on cannabinoid cb1 and cb2 receptors in immune cells. Acta Physiol. 2015;214(1):63-74. [37] NAKAJIMA Y, FURUICHI Y, BISWAS KK, et al. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 2006;580(2):613-619. [38] OSSOLA CA, SURKIN PN, PUGNALONI A, et al. Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflamm Res. 2012;61(9):941-948. [39] KREITZER FR, STELLA N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther. 2009;122(2):83-96. [40] KOZONO S, MATSUYAMA T, BIWASA KK, et al. Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun. 2010;394(4):928‐933. [41] KONERMANN A, JÄGER A, HELD S, et al.In vivo and in vitro identification of endocannabinoid signaling in periodontal tissues and their potential role in local pathophysiology. Cell Mol Neurobiol. 2017;37(8):1511‐1520. [42] GRUDEN G, BARUTTA F, KUNOS G, et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol. 2016; 173(7):1116‐1127. [43] RETTORI E, DE LAURENTIIS A, ZORRILLA ZUBILETE M, et al. Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. Neuroimmunomodulation. 2012;19(5):293-303. [44] LI M, PASCUAL G, GLASS CK. Peroxisome proliferator‐activated receptor gamma‐dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20(13):4699‐4707. [45] STARK JM, COQUET JM, TIBBITT CA. The Role of PPAR-γ in Allergic Disease. Curr Allergy Asthma Rep. 2021;21(11):45. [46] O’SULLIVAN SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899‐1910. [47] YAN W, CAO Y, YANG H, et al. CB1 enhanced the osteo/dentinogenic differentiation ability of periodontal ligament stem cells via p38 MAPK and JNK in an inflammatory environment. Cell Prolif. 2019;52(6):e12691. [48] GOWRAN A, MCKAYED K, CAMPBELL VA. The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation: implications for bone health. Stem Cells Int. 2013;2013:796715. [49] ROSSI F, TORTORA C, PUNZO F, et al. The endocannabinoid/endovanilloid system in bone: from osteoporosis to osteosarcoma. Int J Mol Sci. 2019; 20(8):E1919. [50] WANG L, YANG L, TIAN L, et al. Cannabinoid receptor 1 mediates homing of bone marrow‐derived mesenchymal stem cells triggered by chronic liver injury. J Cell Physiol. 2017;232(1):110‐121. [51] HONG JH, HWANG ES, MCMANUS MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science. 2005;309(5737): 1074‐1078. [52] ASHTON JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs. 2007;8(5):373-384. [53] HU SJ, CHENG G, ZHOU H, et al. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Molecules. 2022;27(3):702. [54] DI MARZO V, BIFULCO M, DE PETROCELLIS L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771-784. [55] HAN S, THATTE J, BUZARD DJ, et al. Therapeutic utility of cannabinoid receptor type 2 (cb(2)) selective agonists. J Med Chem. 2013;56(21):8224-8256. [56] PRESLEY C, ABIDI A, SURYAWANSHI S, et al.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Pharmacol Res Perspect. 2015;3(4):e00159. [57] REINER A, HELDT SA, PRESLEY CS, et al. Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci. 2014;16(1):758-787. [58] KOZONO S, MATSUYAMA T, BIWASA KK, et al. Involvement of the endocannabinoid system in periodontal healing. Biochem Biophys Res Commun. 2010;394(4):928-933. [59] ABIDI AH, ALGHAMDI SS, DABBOUS MK, et al. Cannabinoid type-2 receptor agonist, inverse agonist, and anandamide regulation of inflammatory responses in IL-1β stimulated primary human periodontal ligament fibroblasts. J Periodontal Res. 2020;55(5):762-783. [60] OSSOLA CA, SURKIN PN, MOHN CE, et al. Anti-inflammatory and osteoprotective effects of cannabinoid-2 receptor agonist HU-308 in a rat model of lipopolysaccharide-induced periodontitis. J Periodontol. 2016; 87:725-734. [61] GONDIM DV, ARAÚJO JC, CAVALCANTE AL, et al. CB1 and CB2 contribute to antinociceptive and anti-inflammatory effects of electroacupuncture on experimental arthritis of the rat temporomandibular joint. Can J Physiol Pharmacol. 2012;90:1479-1489. [62] SU TF, ZHAO YQ, ZHANG LH, et al.Electroacupuncture reduces the expression of pro-inflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors. Eur J Pain 2012;16:624-635. [63] KLEIN TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400-411. [64] SUN YX, XU AH, YANG Y, et al. Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells. Biomed Res Int. 2015;2015:874982. [65] FUKUDA S, KOHSAKA H, TAKAYASU A, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskel Dis. 2014;15:275. [66] BAB I, ZIMMER A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008;15:182-188. [67] OFEK O, KARSAK M, LECLERC N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103:696-701. [68] BOYLE WJ, SIMONET WS, LACEY DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342. [69] NAGASAWA T, KIJI M, YASHIRO R, et al. Roles of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol 2000. 2007;43:65-84. [70] TAM J, OFEK O, FRIDE E, et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol. 2006;70:786-792. [71] SCHMUHL E, RAMER R, SALAMON A, et al. Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK. Biochem Pharmacol. 2014;87(3):489-501. [72] QIAN H, ZHAO Y, PENG Y, et al. Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res. 2010;45:504-511. [73] JIRASEK P, JUSKU A, SIMANEK V, et al. Cannabidiol and periodontal inflammatory disease: A critical assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022;166(2):155-160. [74] NOGUEIRA-FILHO GR, TODESCAN S, SHAH A, et al. Impact of Cannabis sativa (marijuana) smoke on alveolar bone loss: a histometric study in rats. J Periodontol. 2011;82:1602-1607. [75] NOGUEIRA-FILHO GR, CADIDE T, ROSA BT, et al. Cannabis sativa smoke inhalation decreases bone filling around titanium implants: a histomorphometric study in rats. Implant Dent. 2008;17: 461-470. [76] SHARIFF JA, AHLUWALIA KP, PAPAPANOU PN. Relationship Between Frequent Recreational Cannabis (Marijuana and Hashish) Use and Periodontitis in Adults in the United States: National Health and Nutrition Examination Survey 2011 to 2012. J Periodontol. 2017;88(3):273-280. [77] PERTWEE RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [78] PATIL CS, KIRKWOOD KL. p38 MAPK signaling in oral‐related diseases. J Dent Res. 2007;86(9):812‐825. [79] BLÜTHGEN N, LEGEWIE S. Systems analysis of MAPK signal transduction. Essays Biochem. 2008;45:95‐107. [80] ZHAO Y, GAO J, ZHANG Y, et al. Cyclosporine A Promotes Bone Remodeling in LPS-Related Inflammation via Inhibiting ROS /ERK Signaling: Studies In Vivo and In Vitro. Oxid Med Cell Longev. 2021;2021:8836599. [81] GALVE‐ROPERH I, CHIURCHIÙ V, DÍAZ‐ALONSO J, et al. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res. 2013;52(4):633‐650. [82] GAO Q, WALMSLEY AD, COOPER PR, et al. Ultrasound stimulation of different dental stem cell populations: role of mitogen‐activated protein kinase signaling. J Endod. 2016;42(3):425‐431. [83] YU Y, MU J, FAN Z, et al. Insulin‐like growth factor 1 enhances the proliferation and osteogenic differentiation of human periodontal ligament stem cells via ERK and JNK MAPK pathways. Histochem Cell Biol. 2012;137(4):513‐525. [84] PAULA‐SILVA FW, GHOSH A, ARZATE H, et al. Calcium hydroxide promotes cementogenesis and induces cementoblastic differentiation of mesenchymal periodontal ligament cells in a CEMP1‐ and ERK‐dependent manner. Calcif Tissue Int. 2010;87(2):144‐157. [85] TSANG EJ, WU B, ZUK P. MAPK signaling has stage‐dependent osteogenic effects on human adipose‐derived stem cells in vitro. Connect Tissue Res. 2018;59(2):129‐146. [86] JIAN CX, FAN QS, HU YH, et al. IL‐7 suppresses osteogenic differentiation of periodontal ligament stem cells through inactivation of mitogen‐activated protein kinase pathway. Organogenesis. 2016;12(4):183‐193. [87] TANG Y, LIU L, WANG P, et al. Periostin promotes migration and osteogenic differentiation of human periodontal ligament mesenchymal stem cells via the Jun amino‐terminal kinases (JNK) pathway under inflammatory conditions. Cell Prolif. 2017;50(6):e12369. [88] ZHUANG H, ZHANG X, ZHU C, et al. Molecular mechanisms of PPAR‐γ governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther. 2016;11(3):255‐264. [89] DENG C, SUN Y, LIU H, et al. Selective adipogenic differentiation of human periodontal ligament stem cells stimulated with high doses of glucose. PLoS ONE. 2018;13(7):e0199603. [90] YAN W, LI L, GE L, et al. The cannabinoid receptor I (CB1) enhanced the osteogenic differentiation of BMSCs by rescue impaired mitochondrial metabolism function under inflammatory condition. Stem Cell Res Ther. 2022;13(1):22. [91] MONTECUCCO F, BURGER F, MACH F, et al. Cb2 cannabinoid receptor agonist jwh-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol. 2008; 294(3):H1145-H1155. [91] WANG J, XU J, PENG Y, et al. Phosphorylation of extracellular signal-regulated kinase as a biomarker for cannabinoid receptor 2 activation. Heliyon. 2018;4(11):e00909. [93] HYTTI M, ANDJELIC S, JOSIFOVSKA N, et al. Cb2 receptor activation causes an erk1/2-dependent inflammatory response in human rpe cells. Sci Rep. 2017;7(1):16169. [94] QI X, LIU C, LI G, et al. Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021;109:103673. [95] ZHU M, YU B, BAI J, et al. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis. J Bone Miner Res. 2019;34(4):739-751. [96] LIU H, ZHOU C, QI D, et al. Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss. Front Cell Dev Biol. 2021;9:640867. [97] JÜTTLER E, POTROVITA I, TARABIN V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology. 2004;47(4):580-592. [98] MAENG YS, MIN JK, KIM JH, et al. Erk is an anti-inflammatory signal that suppresses expression of nf-κb-dependent inflammatory genes by inhibiting ikk activity in endothelial cells. Cell Signal. 2006;18(7):994-1005. [99] MAEDA K, TAKAHASHI N, KOBAYASHI Y. Roles of Wnt signals in bone resorption during physiological and pathological states. Mol Med ( Berl). 2013;91(1):15-23. [100] JIANG T, ZHOU B, HUANG L, et al. Andrographolide Exerts Pro-Osteogenic Effect by Activation of Wnt /β-Catenin Signaling Pathway in Vitro. Cell Physiol Biochem. 2015;36(6):2327-2339. [101] LIU N, SHI S, DENG M, et al. High levels of β-catenin signaling reduce osteogenic differentiation of stem cells in inflammatory microenvironments through inhibition of the noncanonical Wnt pathway. J Bone Miner Res. 2011;26(9):2082-2095. [102] ERN C, BERGER T, FRASHERI I, et al. Differentiation of hMSCs and hPDLSCs induced by PGE2 or BMP-7 in 3D models. Prostaglandins Leukot Essent Fatty Acids. 2017;122:30-37. [103] MAO CY, WANG YG, ZHANG X, et al. Double-edged-sword effect of IL-1β on the osteogenesis of periodontal ligament stem cells via crosstalk between the NF-κB, MAPK and BMP /Smad signaling pathways. Cell Death Dis. 2016;7:e2296. [104] 骆姝含,张岚,黄定明.炎症微环境影响牙周膜干细胞成骨分化的信号通路[J].口腔生物医学,2021,12(2):136-140. [105] DUAN Y, AN W, WU H, et al. Salvianolic Acid C Attenuates LPS-Induced Inflammation and Apoptosis in Human Periodontal Ligament Stem Cells via Toll-Like Receptors 4 ( TLR4) /Nuclear Factor κB ( NF-κB) Pathway. Med Sci Monit. 2019;25:9499-9508. [106] LIU H, ZHENG J, ZHENG T, et al. Exendin-4 regulates Wnt and NFκB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation. Int Immunopharmacol. 2019;75:105801. [107] TANG XL, WANG Y, LI DL, et al. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin. 2012; 33(3):363-371. |
[1] | 方兴艳, 田侦丽, 赵哲仪, 文平, 谢婷婷. 亚砷酸钠对人脐静脉内皮细胞损伤及鞘氨醇激酶1/1-磷酸鞘氨醇信号轴的影响[J]. 中国组织工程研究, 2023, 27(在线): 1-7. |
[2] | 郭淑慧, 杨晔, 江杨洋, 许建文. 神经源性膀胱miRNA-mRNA调控网络的筛选与验证[J]. 中国组织工程研究, 2023, 27(在线): 1-8. |
[3] | 高 煜, 韩佳慧, 葛 新. 脊髓缺血再灌注损伤后的免疫炎性微环境[J]. 中国组织工程研究, 2023, 27(8): 1300-1305. |
[4] | 王 敏, 尹秀山, 王盈熹, 张 妍, 赵 龙, 夏书月. 吸入骨髓间充质干细胞来源外泌体减轻慢性阻塞性肺疾病的炎性损伤[J]. 中国组织工程研究, 2023, 27(6): 827-834. |
[5] | 李 龙, 李光第, 石 豪, 邓柯淇. 环状RNA作为内源性竞争RNA参与调控骨性关节炎的发生[J]. 中国组织工程研究, 2023, 27(5): 751-757. |
[6] | 李志超, 谭国庆, 苏 辉, 徐展望, 薛海鹏. 非编码RNAs作为潜在治疗靶点在脊髓损伤中的调控效应[J]. 中国组织工程研究, 2023, 27(5): 758-764. |
[7] | 邵子晨, 李华南, 顾 兵, 章晓云, 孙伟康, 刘永钱, 甘 斌. 痛风过程中微小RNA、长链非编码RNA和环状RNA介导降尿酸、抗炎及调控骨代谢的协同调节作用[J]. 中国组织工程研究, 2023, 27(5): 765-771. |
[8] | 张力宸, 陈 亮, 顾 勇. 无机离子仿生骨膜调控免疫微环境促进骨修复[J]. 中国组织工程研究, 2023, 27(3): 346-353. |
[9] | 陈 财, 曾 平, 刘金富. 介导软骨细胞相关机制调控骨性关节炎的长链非编码RNA[J]. 中国组织工程研究, 2023, 27(29): 4729-4735. |
[10] | 陈柏豪, 何 琪, 杨均政, 潘兆丰, 肖嘉聪, 黎 淼, 黎少聪, 曾嘉旭, 王海彬, 郑 稼, 张 濛. Piezo1蛋白在股骨头坏死发病机制中的意义[J]. 中国组织工程研究, 2023, 27(27): 4414-4420. |
[11] | 赵紫瑞, 胡乔禹, 齐 霞, 刘 庆. 代谢组学技术对牙周炎生物标志物、病理机制及与全身关系的评价[J]. 中国组织工程研究, 2023, 27(26): 4239-4245. |
[12] | 黄少烁, 李嘉程, 骆 帝, 朱 凯, 许 波, 薛远亮, 阎博昭, 李 刚. 黄芪甲苷可减轻白细胞介素1β诱导软骨细胞的炎症反应[J]. 中国组织工程研究, 2023, 27(26): 4113-4119. |
[13] | 方兴艳, 田侦丽, 赵哲仪, 文 平, 谢婷婷. 亚砷酸钠对人脐静脉内皮细胞损伤及鞘氨醇激酶1/1-磷酸鞘氨醇信号轴的影响[J]. 中国组织工程研究, 2023, 27(26): 4161-4167. |
[14] | 邓墨渊, 彭 坤. 巨噬细胞及其特异性调控在生物材料纤维化形成中的作用[J]. 中国组织工程研究, 2023, 27(25): 4085-4092. |
[15] | 王东旭, 任 晶, 李吉萍, 王玉俗, 胡鹏飞, 张国坤, 李春义. 鹿茸干细胞来源外泌体调控NF-κB信号通路预防小鼠酒精性肝损伤[J]. 中国组织工程研究, 2023, 27(24): 3824-3830. |
1.1.7 检索策略 以 PubMed数据库检索策略为例,见图1。
1.1.8 检索文献量 共检索到文献3 194 篇。
1.3 数据的提取 共检索到文献3 194篇,排除不同数据库以及平台中与研究目的相关性差及内容陈旧、质量不高、重复的文献 3 087篇,纳入107篇符合标准的文献进行综述,其中英文文献106篇,中文文献1篇,分别探讨 CB1 受体、CB2 受体与牙周炎的关系。文献检索流程图见图2。
文题释义:
大麻素受体(Cannabinoid receptors,CBRs):是A类GPCRs家族的成员,其中最具有代表性的为大麻素Ⅰ型(CB1)受体、大麻素Ⅱ型(CB2)受体,为内源性大麻素系统的两种典型受体。CBRs在成骨细胞、破骨细胞等细胞表面表达,可作为靶点与大麻素配体结合,参与调节成骨细胞、破骨细胞活性,对局部炎症和免疫功能也有一定的调控作用。阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||